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Abstract
BACKGROUND—Sentinel-lymph-node biopsy is associated with increased melanoma-specific 
survival (i.e., survival until death from melanoma) among patients with node-positive 
intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node 
dissection for patients with sentinel-node metastases is not clear.
METHODS—In an international trial, we randomly assigned patients with sentinel-node 
metastases detected by means of standard pathological assessment or a multimarker molecular 
assay to immediate completion lymph-node dissection (dissection group) or nodal observation 
with ultrasonography (observation group). The primary end point was melanoma-specific survival. 
Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node 
metastasis.
RESULTS—Immediate completion lymph-node dissection was not associated with increased 
melanoma-specific survival among 1934 patients with data that could be evaluated in an intention-
to-treat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, 
the mean (±SE) 3-year rate of melanoma-specific survival was similar in the dissection group and 
the observation group (86±1.3% and 86±1.2%, respectively; P=0.42 by the log-rank test) at a 
median follow-up of 43 months. The rate of disease-free survival was slightly higher in the 
dissection group than in the observation group (68±1.7% and 63±1.7%, respectively; P=0.05 by 
the log-rank test) at 3 years, based on an increased rate of disease control in the regional nodes at 3 
years (92±1.0% vs. 77±1.5%; P<0.001 by the log-rank test); these results must be interpreted with 
caution. Nonsentinel-node metastases, identified in 11.5% of the patients in the dissection group, 
were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005). 
Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those 
in the observation group.
CONCLUSIONS—Immediate completion lymph-node dissection increased the rate of regional 
disease control and provided prognostic information but did not increase melanoma-specific 
survival among patients with melanoma and sentinel-node metastases. (Funded by the National 
Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895.)
Address reprint requests to Dr. Faries at 11818 Wilshire Blvd., Suite 200, Los Angeles, CA 90025, or at mfaries@theangelesclinic.org. 
The authors’ full names, academic degrees, and affiliations are listed in the Appendix.
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Sentinel-lymph-node biopsy is a standard procedure in the care of appropriately selected 
patients with melanoma. The first Multicenter Selective Lymphadenectomy Trial (MSLT-I) 
confirmed the value of early nodal evaluation and treatment.1–3 This prospective, 
international, randomized trial showed that the pathologic status of the sentinel node or 
nodes was the most important prognostic factor and that patients who underwent sentinel-
node biopsy had fewer recurrences of melanoma than patients who underwent wide excision 
and nodal observation. Among patients with intermediate-thickness melanomas (defined as 
1.2 to 3.5 mm) and nodal metastases, early surgical treatment, guided by sentinel-node 
biopsy, was associated with increased melanoma-specific survival (survival until death from 
melanoma). These results provide support for the recommendation by several professional 
organizations that staging by means of sentinel-node biopsy should be performed when 
appropriate.4–7
Currently, immediate completion lymph-node dissection (removal of the remaining regional 
lymph nodes after sentinel-node excision) is usually recommended for patients with 
sentinel-node metastases. However, prospective evidence of the efficacy of completion 
lymph-node dissection is lacking, and the procedure carries a risk of adverse events.8 Results 
of retrospective evaluations of the usefulness of completion lymph-node dissection are 
inconclusive.9–11 Available data from one prospective study do not suggest a benefit from 
immediate dissection, but this study is not sufficiently powered to rule out a clinically 
significant benefit.12 In addition, in most patients, nodal disease is limited to the sentinel 
lymph node or nodes and is removed by means of biopsy. Conversely, patients with even 
microscopic involvement of nonsentinel nodes have an overall poorer prognosis and 
outcomes that are similar to those in patients with clinically apparent nodal disease.13,14
In the second Multicenter Selective Lymphadenectomy Trial (MSLT-II), we evaluated the 
usefulness of completion lymph-node dissection in patients with melanoma and sentinel 
lymph-node metastases as compared with observation with frequent nodal ultrasonography 
and dissection only in patients in whom clinically detected nodal recurrence had developed.
METHODS
TRIAL DESIGN AND OVERSIGHT
MSLT-II, an international, multicenter, randomized, phase 3 trial to evaluate the usefulness 
of completion lymph-node dissection in patients with melanoma and sentinel-node 
metastases, consisted of a screening phase in which patients were enrolled before sentinel-
node biopsy and a randomization phase in which completion lymph-node dissection was 
compared with observation and nodal ultrasonography (Fig. 1). The trial was conducted at 
63 centers.
MSLT-II was designed by the MSLT-II executive committee with input from the pathology 
and ultrasonography oversight committees (see the Supplementary Appendix, available with 
the full text of this article at NEJM.org). Data were collected prospectively on paper and 
later on Web-based case-report forms. The authors vouch for the accuracy and completeness 
of the data and analyses reported and for the fidelity of the trial to the protocol, available at 
NEJM.org.
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Nodal metastasis was determined by means of standard pathological assessment (including 
immunohistochemical tests performed according to institutional protocols) or by means of a 
previously described quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) 
assay during the screening phase.15 Patients had to have undergone randomization and 
completion lymph-node dissection within 140 days after diagnostic biopsy.
The randomization phase involved enrollment of patients who had undergone screening and 
had pathologically or molecularly positive sentinel-node metastases and patients who had 
not undergone screening in whom sentinel-node metastases were detected by means of 
pathological assessment. In the randomization phase, fewer patients with RT-PCR–positive 
findings than anticipated were enrolled. In 2012, the data and safety monitoring board 
determined that such patients should no longer undergo randomization, since attainment of 
sufficient power to evaluate a therapeutic effect in that group was not feasible. The data and 
safety monitoring board recommended continued follow-up of these patients to assess 
outcomes.
At the third interim analysis, the data and safety monitoring board determined that detection 
of a significant survival difference between the trial groups was unlikely and recommended 
that the current primary end-point data be released. Intention-to-treat and per-protocol 
analyses of the outcome variables showed similar results. Results of per-protocol analyses 
are reported in this article, since they are likely to be the most clinically pertinent. The 
intention-to-treat data for the primary end point (melanoma-specific survival) are provided 
in Figure S1 in the Supplementary Appendix.
PATIENTS
Eligible patients who provided written informed consent were randomly assigned to undergo 
completion lymph-node dissection or nodal observation. These patients were 18 to 75 years 
of age and had clinically localized cutaneous melanoma, an Eastern Cooperative Oncology 
Group performance status of 0 or 1 (on a 5-point scale, with 0 indicating an absence of 
disability and higher numbers indicating greater disability), a non–melanoma-related life 
expectancy of 10 years or more, and a tumor-positive sentinel node. The trial was opened 
before the universal application of registration. The trial opened in December 2004 and was 
registered at Clinicaltrials.gov on February 27, 2006. At the time of registration, 119 patients 
had been enrolled in the trial.
Randomization was performed in a 1:1 ratio with the use of a permuted-block design, which 
was stratified according to Breslow thickness, ulceration, method of metastasis detection 
(standard pathological assessment or RT-PCR assay), and enrollment at an MSLT-I center. 
Patients who were assigned to the observation group were monitored by means of clinical 
examination every 4 months during the first 2 years, every 6 months during years 3 through 
5, and then annually. Nodal ultrasonographic assessment of the sentinel-node basin occurred 
at each visit for the first 5 years; findings were considered to be abnormal on the basis of a 
length:depth ratio of less than 2, a hypoechoic center, an absence of hilar vessels, or focal 
nodularity with increased vascularity. Follow-up of the dissection group involved the same 
schedule, but without protocol-mandated nodal ultrasonography.
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STATISTICAL ANALYSIS
For the primary end point, melanoma-specific survival, we used the log-rank test to compare 
the rates among patients in the dissection group and the observation group in the intention-
to-treat population. Secondary end points included overall survival, disease-free survival, 
survival without recurrence of regional nodal metastases, distant metastasis–free survival, 
and the extent of nodal involvement. Time zero was the time of randomization. Melanoma-
specific survival was determined at the time of melanoma-related death. Disease-free 
survival was the time to any recurrence. Survival without nodal recurrence was the time to 
recurrence within the draining nodal basin. For survival, comparisons between the two 
groups were performed by means of the log-rank test for univariable testing and Cox 
regression for adjusted comparisons. Nodal recurrence occurred in a draining regional basin, 
local and in-transit recurrence occurred between the primary site and the regional basin, and 
distant recurrence occurred beyond the regional basin.
We estimated that with a total sample of 1925 patients, the trial would have a power of 83% 
to detect a between-group difference of 5 percentage points in melanoma-specific survival. 
All tests were two-tailed. Power was reassessed by the data and safety monitoring board 
before closure of enrollment to ensure that an adequate sample size had been obtained. The 
cumulative rate of nonsentinel-node metastases was determined by clinical follow-up in the 
observation group and according to total in-basin nodal recurrence or nonsentinel-node 
metastasis on immediate completion lymph-node dissection in the dissection group.
Data were summarized with means and standard deviations, medians and ranges, or both in 
the intention-to-treat and per-protocol analyses. Chi-square and Wilcoxon rank-sum tests 
were used to compare results for patients in the dissection group who actually underwent 
completion lymph-node dissection (these patients were included in the per-protocol and 
intention-to-treat analyses) with results for those who did not undergo the assigned 
completion lymph-node dissection (these patients were included only in the intention-to-
treat analysis). Survival curves were computed with the use of the Kaplan–Meier method 
and stratified according to group alone or according to group and method of metastasis 
detection (pathological assessment vs. RT-PCR). Cox proportional-hazards regression 
models were constructed separately for the two groups; these models included demographic 
factors, trial stratification factors, and nonsentinel-node metastasis at the time of completion 
lymph-node dissection. Subgroup analyses included subgroups that were defined according 
to the patients’ sex and age, the Breslow thickness, the location and number of positive 
nodes, and the presence or absence of ulceration. Cox proportional-hazards regression was 
used to estimate the subgroup-specific hazard ratios.
RESULTS
PATIENTS
From December 2004 through March 2014, a total of 3531 patients were enrolled in the 
screening phase and 1939 patients underwent randomization (Fig. 1). Demographic and 
pathologic features of the dissection and observation groups were similar (Table 1, and Table 
S1 in the Supplementary Appendix). A greater proportion of patients assigned to completion 
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lymph-node dissection than to observation declined their assigned treatment. However, the 
per-protocol cohorts were similar with respect to prognostic factors (Table 1).
In the dissection group, 143 patients were excluded from the per-protocol analysis. Of those 
patients, 140 declined the assigned treatment. Patients who were excluded from the per-
protocol analysis were more likely than patients who were not excluded to have never 
smoked, to have nonulcerated primary tumors, and to have an RT-PCR–positive sentinel 
node (Table S2 in the Supplementary Appendix). The sentinel-node tumor burden in both 
groups was low; the median diameter of the largest tumor deposit was 0.61 mm in the 
dissection group and 0.67 mm in the observation group.
SURVIVAL RATES
At 3 years of follow-up, there was no significant difference in the mean (±SE) rate of 
melanoma-specific survival between the dissection group and the observation group in the 
per-protocol analysis (86±1.3% and 86±1.2%, respectively; P=0.42 by the log-rank test) 
(Fig. 2A) or the intention-to-treat analyses (Fig. S1 in the Supplementary Appendix). In 
addition, there was no significant between-group difference in melanoma-specific survival 
after adjustment for other prognostic factors (hazard ratio for death, 1.08; 95% confidence 
interval [CI], 0.88 to 1.34; P = 0.42).
An analysis with available follow-up data suggested that an RT-PCR–positive sentinel node 
did not have an effect on survival that was as negative as the effect anticipated in the 
statistical design of the trial, so the results from the two groups are also reported separately 
here and in the remaining analyses (Fig. 2B). The results of an analysis of both groups 
together are shown in Figure S2 in the Supplementary Appendix. A subgroup analysis, 
including an analysis based on sentinel-node tumor burden, did not reveal any subgroups 
that derived a significant melanoma-specific survival benefit from completion lymph-node 
dissection (Fig. S3 in the Supplementary Appendix).
At 3 years of follow-up, the rate of disease-free survival was slightly higher in the dissection 
group than in the observation group (68±1.7% and 63±1.7%, respectively; P=0.05 by the 
log-rank test) (Fig. 3A, and Fig. S2A in the Supplementary Appendix), although the results 
of secondary outcome analyses must be viewed cautiously given the lack of significance for 
the primary end point. This difference in disease-free survival appears to result from a 
reduction in the rate of nodal recurrence after completion lymph-node dissection (Fig. 3B, 
and Fig. S2B in the Supplementary Appendix). This corresponds to an increase in the rate of 
disease control in the regional nodes at 3 years (92±1.0% in the dissection group vs. 
77±1.5% in the observation group, P<0.001 by the log-rank test). After adjustment, the rate 
of nodal recurrence among patients with sentinel-node metastases detected by means of 
pathological assessment was 69% lower in the dissection group than in the observation 
group (hazard ratio, 0.31; 95% CI, 0.24 to 0.41; P<0.001). No significant between-group 
difference in distant metastasis–free survival was detected (adjusted hazard ratio, 1.10; 95% 
CI, 0.92 to 1.31; P = 0.31) (Fig. 3C, and Fig. S2C in the Supplementary Appendix). Types of 
initial recurrence are listed in Table S4 in the Supplementary Appendix.
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PROGNOSTIC FACTORS
Potential prognostic factors affecting melanoma-specific survival were examined. Since the 
pathologic status of nonsentinel nodes was unknown in the observation group, the two 
groups of the trial were considered separately. In the entire trial (including patients with 
positive RT-PCR results), Breslow thickness and the number of sentinel nodes that were 
positive on pathological assessment (0 vs. >0) were significant prognostic factors in both 
groups, and male sex was a significant prognostic factor in the observation group (Table S3 
in the Supplementary Appendix). However, since the RT-PCR group appeared to be 
prognostically distinct, an analysis was also performed that included only patients with 
sentinel nodes that were positive on pathological assessment (Table 2). In the observation 
group, male sex was no longer a significant prognostic factor, and it remained nonsignificant 
in the dissection group. Breslow thickness was a significant prognostic factor in both groups, 
and the pathologic status of nonsentinel nodes was a significant prognostic factor in the 
dissection group (hazard ratio for death, 1.78; P = 0.005). The number of involved sentinel 
nodes was not a significant prognostic factor.
Among patients who underwent immediate completion lymph-node dissection, nonsentinel-
node metastases were detected on pathological assessment in 11.5%, and over time, with 
nodal recurrences in that group, the percentage of patients in whom nonsentinel-node 
metastases were detected increased to an actuarial rate of 17.9% at 3 years and 19.9% at 5 
years (Fig. 3D). In the observation group, the percentage of patients in whom 
ultrasonographic or physical examination revealed involved nonsentinel nodes increased to 
22.9% at 3 years and 26.1% at 5 years, exceeding the rate in the dissection group at both 
time points (P = 0.02 and P = 0.005, respectively).
ADVERSE EVENTS
Adverse events were more common among patients after completion lymph-node dissection 
than among patients in the observation group. At the most recent follow-up on April 30, 
2016, a total of 24.1% of the patients in the dissection group and 6.3% of those in the 
observation group had had lymphedema (P<0.001). Among the patients who had 
lymphedema, this condition was mild in 64%, moderate in 33%, and severe in 3%.
DISCUSSION
The management of regional lymph nodes has long been controversial in the treatment of 
many solid tumors, particularly melanoma.16 The MSLT-I confirmed the staging value of 
sentinel-node biopsy and showed a therapeutic advantage of early treatment of nodal 
metastases among patients with intermediate-thickness melanoma.3 The findings of that trial 
provided support for the use of sentinel-node biopsy, which is now recommended in the 
guidelines of most national and professional organizations for the treatment of melanoma.4–7
However, in patients with sentinel-node metastases, the value of completion lymph-node 
dissection remains controversial. Since most such patients have all nodal metastases 
removed by means of the sentinel-node biopsy procedure, they cannot derive additional 
therapeutic value from completion lymph-node dissection. Even microscopic nonsentinel-
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node metastases portend a markedly worse prognosis, similar to that of patients with bulky, 
clinically diagnosed metastases,13,14 than the prognosis in patients with metastases that are 
limited to the sentinel lymph nodes. Patients with nonsentinel-node metastasis may be 
unlikely to benefit from early dissection. Finally, completion lymph-node dissection is 
associated with higher morbidity than sentinel-node biopsy alone, so an appraisal of the 
value of the procedure is important.
Previous data regarding this clinical question have been inconclusive. Retrospective series 
have produced varied results and are subject to a considerable risk of selection bias.9–11 The 
findings of one prospective study were similar to those in our trial, but its size (483 patients 
underwent randomization) and most recent follow-up left enough statistical uncertainty to 
preclude definitive conclusions.12 MSLT-II, in which 1939 patients underwent 
randomization with a median follow-up of 43 months, provided sufficient data to resolve the 
central question: no significant survival benefit was imparted by immediate completion 
lymph-node dissection among patients with sentinel-node metastases. However, completion 
lymph-node dissection did provide other potential value for patients with melanoma, 
including improved staging and an increased rate of regional disease control.
Most patients in the trial population had a low-volume nodal tumor burden. Indeed, some 
patients had only molecular indications of melanoma in the sentinel node, determined by 
means of RT-PCR. Those patients had outcomes that were not as poor as those in 
retrospective studies using the same assay.15,17 However, any variance from pretrial event-
rate estimates is unlikely to have affected the overall result, since the RT-PCR–positive 
group constituted only 12% of the randomized study population. Furthermore, the number of 
patients with pathologically detected metastases actually exceeded the number in the 
statistical plan. Patients with a larger sentinel-node tumor burden are more likely than 
patients with a smaller burden to have nonsentinel-node metastases, and the small number of 
patients with a larger sentinel-node tumor burden in this trial limits statistical confidence for 
those patients specifically. It may be possible to use an estimation of the risk of nonsentinel-
node metastases based on sentinel-node tumor burden and primary tumor characteristics to 
help identify patients who may benefit from completion lymph-node dissection.18–20 
However, a subgroup evaluation of patients with a greater disease burden (maximal tumor 
diameter >1 mm) did not indicate that a benefit from completion lymph-node dissection was 
more likely in high-risk groups than in low-risk groups.
The current trial confirms that the pathologic status of nonsentinel nodes has independent 
prognostic value, whereas the number of involved sentinel nodes was not significantly 
related to melanoma-specific survival. Although this finding is somewhat counterintuitive, it 
echoes retrospective data from multiple institutions.13,14 This confirmation in a prospective 
trial of the large effect of nonsentinel node status on prognosis reaffirms its staging value. A 
lack of this information may impede the most appropriate risk stratification and selection of 
adjuvant therapy for patients who do not undergo completion lymph-node dissection.
Immediate completion lymph-node dissection reduced the rate of regional nodal recurrence 
by nearly 70%, leading to a small but significant decrease in the overall risk of recurrence. 
Since no significant difference between the groups was noted in the primary end point, 
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differences with respect to the secondary end points must be interpreted with caution. A 
nonsignificant difference in distant metastasis–free survival was noted at late time points, but 
as of this writing, events at those time points have been few, and additional follow-up is 
necessary. Our trial was unable to determine the safety of avoiding completion lymph-node 
dissection in patients who are unable to undergo frequent follow-up evaluations or in 
patients who receive treatment at institutions that are not able to perform nodal 
ultrasonography.
The advantages of immediate completion lymph-node dissection are tempered by the 
complications of the procedure. As of this writing, lymphedema has been observed in 24% 
of the patients in the dissection group and 6% of the patients in the observation group. As 
expected, there were significantly more complications among patients who underwent 
completion lymph-node dissection than among those who did not, although the adverse 
events associated with the surgical procedure were often transient. Although a complete 
assessment and comparison of lymphedema with other complications would require 
additional follow-up, we think that the decreased overall number of dissections among 
patients in the observation group will translate into decreased complications.
The lack of a survival advantage associated with immediate completion lymph-node 
dissection in this trial contrasts with the results of the MSLT-I. In that trial, patients with 
nodal disease and intermediate-thickness melanomas had better outcomes with immediate 
surgery than with delayed surgery. The lack of a survival benefit with completion lymph-
node dissection in patients in MSLT-II suggests that any increase in survival with early 
surgery occurred among patients with disease that was limited to the sentinel node. Patients 
with nonsentinel-node metastases may still undergo salvage treatment with completion 
lymph-node dissection, but the timing of that intervention does not appear to be critical.
Early completion lymph-node dissection did not increase survival in the MSLT-II 
population. It is possible that this was due to dilution of a therapeutic effect, since 
approximately three quarters of the population did not have melanoma in nonsentinel nodes. 
A comparison of results in patients with nonsentinel-node metastases in this trial, similar to 
the latent subgroup analysis in MSLT-I, might address this possibility, but it would be 
difficult to accomplish.21 First, in this population with a low disease burden and with the 
most recent follow-up, additional nodal recurrences are expected. Second, even at the most 
recent follow-up, an imbalance in the observed proportion of patients with non-sentinel 
node–positive disease was noted, with an excess in the observation group. This may be due 
to small nonsentinel-node metastases that were not detected on standard pathological 
examination. Intensive evaluation of nonsentinel nodes with the use of 
immunohistochemical tests indicates that the frequency of these occult metastases in 
completion lymph-node dissection specimens is very similar to that of excess nodal 
recurrences (8 to 10%).18
Overall, some value may be derived from immediate completion lymph-node dissection with 
regard to staging and an increased rate of regional disease control. However, this value 
comes at the cost of increased complications.
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Figure 1. Trial Design, Enrollment, and Outcomes
RT-PCR denotes reverse-transcriptase polymerase chain reaction.
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Figure 2. Melanoma-Specific Survival, According to Trial Group and Method of Detection of 
Metastasis
Panel A shows melanoma-specific survival according to trial group (completion lymph-node 
dissection or observation) in the per-protocol analysis. Panel B shows melanoma-specific 
survival according to the method of detection of sentinel-node metastasis (RT-PCR or 
pathological assessment). Subgroup 1 comprised patients in the dissection group with 
pathologically detected metastases; subgroup 2, patients in the observation group with 
pathologically detected metastases; subgroup 3, those in the dissection group with RT-PCR–
detected metastases; and subgroup 4, those in the observation group with RT-PCR–detected 
metastases. P values were calculated with the use of log-rank tests.
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Figure 3. Disease-free Survival, Survival without Nodal Recurrence, and Distant Metastasis–free 
Survival, According to Trial Group, and the Cumulative Rate of Nonsentinel-Node Metastasis
Panel A shows disease-free survival, Panel B shows survival without nodal recurrence, and 
Panel C shows distant metastasis–free survival according to trial group (completion lymph-
node dissection or observation). Subgroup 1 comprised patients in the dissection group with 
pathologically detected metastases; subgroup 2, patients in the observation group with 
pathologically detected metastases; subgroup 3, those in the dissection group with RT-PCR–
detected metastases; and subgroup 4, those in the observation group with RT-PCR–detected 
metastases. Panel D shows the cumulative rate of nonsentinel-node metastasis among 
patients in the dissection group who had positive findings on pathological assessment or 
nodal recurrence and among patients in the observation group who had nodal recurrence. P 
values were calculated with the use of log-rank tests.
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Table 1
Baseline Characteristics of the Patients in the Per-Protocol Analysis.*
Characteristic Dissection (N = 824) Observation (N = 931)
Sex — no. (%)
 Female 346 (42.0) 382 (41.0)
 Male 478 (58.0) 549 (59.0)
Age — yr
 Mean 52.5±12.9 53.2±13.6
 Median (range) 53.7 (18–76) 54.9 (19–76)
Smoking status — no./total no. (%)†
 Never 463/803 (57.7) 522/907 (57.6)
 Former 193/803 (24.0) 227/907 (25.0)
 Current 147/803 (18.3) 158/907 (17.4)
Breslow thickness
 Mean — mm 2.76±2.34 2.70±2.11
 Median (range) — mm 2.10 (0.34–28.0) 2.10 (0.35–30.0)
 <1.50 mm — no. (%) 237 (28.8) 257 (27.6)
 1.50–3.50 mm — no. (%) 404 (49.0) 462 (49.6)
 >3.50 mm — no. (%) 183 (22.2) 212 (22.8)
Primary site — no. (%)
 Arm or leg 327 (39.7) 382 (41.0)
 Head or neck 113 (13.7) 128 (13.7)
 Trunk 384 (46.6) 421 (45.2)
Ulceration — no. (%)
 Absent 508 (61.7) 578 (62.1)
 Present 316 (38.3) 353 (37.9)
No. of positive sentinel lymph nodes — no. of patients (%)
 0, RT-PCR–positive 80 (9.7) 111 (11.9)
 1 596 (72.3) 643 (69.1)
 2 121 (14.7) 162 (17.4)
 3 18 (2.2) 10 (1.1)
 >3 9 (1.1) 5 (0.5)
Diameter of sentinel-lymph-node metastasis — mm‡
 Mean 1.07 1.11
 Median 0.61 0.67
 Interquartile range 0.27–1.32 0.23–1.38
Size of sentinel-lymph-node metastasis — no. of patients/total no. (%)
 <0.1 mm 45/566 (8.0) 65/623 (10.4)
 0.1–1.0 mm 333/566 (58.8) 343/623 (55.1)
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Characteristic Dissection (N = 824) Observation (N = 931)
 >1.0 mm 188/566 (33.2) 215/623 (34.5)
Received adjuvant therapy — no./total no. (%)§ 66/814 (8.1) 60/922 (6.5)
*
Plus–minus values are means ±SD. There were no significant between-group differences in the characteristics listed here. Percentages may not 
total 100 because of rounding. RT-PCR denotes reverse-transcriptase polymerase chain reaction.
†
Data were missing for 21 patients in the dissection group and 24 patients in the observation group.
‡
The sentinel-node metastasis burden, the longest diameter of the largest tumor deposit, was not available for 178 patients in the dissection group 
and 197 patients in the observation group.
§
Data were not available for 10 patients in the dissection group and 9 patients in the observation group.
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Table 2
Hazard Ratios for Melanoma-Related Death, According to Multivariable Prognostic Factors.*
Prognostic Factor Dissection Observation
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Sex: male vs. female 1.13 (0.80–1.59) 0.50 1.41 (0.98–2.05) 0.07
Age, per 1-yr increase 1.00 (0.99–1.01) 0.93 1.01 (0.99–1.02) 0.15
Breslow thickness
 <1.50 mm† 1.00 1.00
 1.50–3.50 mm 1.64 (0.96–2.79) 0.07 2.46 (1.34–4.53) 0.004
 >3.50 mm 3.82 (2.19–6.66) <0.001 4.32 (2.31–8.09) <0.001
Ulceration: present vs. absent 1.97 (1.40–2.77) <0.001 2.17 (1.55–3.05) <0.001
Site of melanoma
 Arm or leg† 1.00 1.00
 Head or neck 0.81 (0.44–1.48) 0.49 1.60 (0.96–2.66) 0.07
 Trunk 1.26 (0.89–1.77) 0.19 1.05 (0.74–1.49) 0.80
No. of positive sentinel nodes
 1† 1.00 1.00
 2 1.08 (0.71–1.62) 0.73 1.27 (0.87–1.84) 0.21
 ≥3 1.17 (0.61–2.24) 0.64 2.01 (0.82–4.95) 0.13
Nonsentinel nodes: positive vs. negative 1.78 (1.19–2.67) 0.005 NA
*
Patients with positive findings on RT-PCR were excluded from this analysis. NA denotes not applicable.
†
This group served as the reference group.
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